Results 221 to 230 of about 29,030 (239)

Natalizumab

Reactions Weekly, 2018
  +4 more sources

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

Lancet Neurology, The, 2010
David B Clifford, Avindra Nath, Andrea De Luca   +2 more
exaly  

Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab‐associated progressive multifocal leukoencephalopathy

Annals of Neurology, 2014
Denise Campagnolo
exaly  

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

Lancet Oncology, The, 2009
Kenneth R Carson, Daniele Focosi, Charles L Bennett   +2 more
exaly  

Natalizumab

Reactions Weekly, 2008
openaire   +1 more source

Natalizumab

Reactions Weekly, 2010
openaire   +2 more sources

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

Lancet Neurology, The, 2009
Eva Kubala Havrdova, Michael Hutchinson, Gavin Giovannoni   +2 more
exaly  

Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial

Gastroenterology, 2007
Richard Fedorak, Remo Panaccione
exaly  

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

Annals of Neurology, 2016
Peter Alping, Thomas Frisell, Jonatan Salzer   +2 more
exaly  

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

Lancet Neurology, The, 2007
Ludwig Kappos, Eva Kubala Havrdova, David B Clifford   +2 more
exaly